Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Polina Kaplan, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna M. Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki FujisakiMamta Garg, Christopher Chiu, Jianping Wang, Robin Carson, Wendy Crist, William Deraedt, Huong Nguyen, Ming Qi, Jesus San-Miguel

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)518-528
Number of pages11
JournalNew England Journal of Medicine
Volume378
Issue number6
DOIs
Publication statusPublished - Dec 12 2017
Externally publishedYes

Cite this

Mateos, M-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., Pour, L., Cook, M., Grosicki, S., Crepaldi, A., Liberati, A. M., Campbell, P., Shelekhova, T., Yoon, S-S., Iosava, G., ... San-Miguel, J. (2017). Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine, 378(6), 518-528. https://doi.org/10.1056/NEJMoa1714678